It should be noted, though, that NK cell inhibition via KIR/HLA-A, -B, and -C interactions shall be confirmed with EBV+ targets other than LCLs, for instance, EBV-associated tumors in which HLA class I molecules can be downregulated also by cellular oncogenic factors, as shown for c-Myc in the context of NPC (54). The gene discussed is KIR3DL1; the disease is nasopharyngeal carcinoma.